JP2024517738A5 - - Google Patents

Info

Publication number
JP2024517738A5
JP2024517738A5 JP2023566493A JP2023566493A JP2024517738A5 JP 2024517738 A5 JP2024517738 A5 JP 2024517738A5 JP 2023566493 A JP2023566493 A JP 2023566493A JP 2023566493 A JP2023566493 A JP 2023566493A JP 2024517738 A5 JP2024517738 A5 JP 2024517738A5
Authority
JP
Japan
Prior art keywords
composition according
minutes
dmt
approximately
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517738A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026396 external-priority patent/WO2022232179A1/en
Publication of JP2024517738A publication Critical patent/JP2024517738A/ja
Publication of JP2024517738A5 publication Critical patent/JP2024517738A5/ja
Pending legal-status Critical Current

Links

JP2023566493A 2021-04-26 2022-04-26 新規のn,n-ジメチルトリプタミン組成物および方法 Pending JP2024517738A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163179679P 2021-04-26 2021-04-26
US63/179,679 2021-04-26
PCT/US2022/026396 WO2022232179A1 (en) 2021-04-26 2022-04-26 Novel n,n-dimethyltryptamine compositions and methods

Publications (2)

Publication Number Publication Date
JP2024517738A JP2024517738A (ja) 2024-04-23
JP2024517738A5 true JP2024517738A5 (cg-RX-API-DMAC7.html) 2025-05-07

Family

ID=83694712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566493A Pending JP2024517738A (ja) 2021-04-26 2022-04-26 新規のn,n-ジメチルトリプタミン組成物および方法

Country Status (12)

Country Link
US (1) US11602521B2 (cg-RX-API-DMAC7.html)
EP (1) EP4329879A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517738A (cg-RX-API-DMAC7.html)
KR (1) KR20240000516A (cg-RX-API-DMAC7.html)
CN (1) CN117320711A (cg-RX-API-DMAC7.html)
AU (1) AU2022267240A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022195A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216889A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003191A1 (cg-RX-API-DMAC7.html)
IL (1) IL308074A (cg-RX-API-DMAC7.html)
MX (1) MX2023012651A (cg-RX-API-DMAC7.html)
WO (1) WO2022232179A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753923A1 (en) 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
EP3868364A1 (en) 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
KR20250005182A (ko) * 2022-03-27 2025-01-09 지에이치 리서치 아일랜드 리미티드 인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민
EP4608395A2 (en) * 2022-10-26 2025-09-03 ATAI Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
DK202330319A1 (en) * 2023-11-07 2025-05-27 Fertin Pharma As An adhesive oral disc for sustained release of cannabinoids
US20240325351A1 (en) 2023-03-31 2024-10-03 Cybin UK Ltd. Method of administration
EP4773958A1 (en) * 2023-09-08 2026-07-15 ATAI Therapeutics, Inc. Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
EP4788322A1 (en) * 2023-10-02 2026-08-12 ATAI Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60215685A (ja) * 1984-04-11 1985-10-29 Takeda Chem Ind Ltd 2’−デオキシアリステロマイシン誘導体およびその用途
US20220079881A1 (en) 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
DK3927338T3 (da) * 2019-02-22 2025-01-06 Gh Res Ireland Limited Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
HUE066828T2 (hu) 2019-02-22 2024-09-28 Gh Res Ireland Limited 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
KR102946120B1 (ko) * 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
WO2020176597A1 (en) * 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
WO2021003467A1 (en) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US20210023052A1 (en) * 2019-07-23 2021-01-28 Caamtech Llc Compositions containing toad secretion compounds
WO2021041407A1 (en) * 2019-08-25 2021-03-04 Caamtech Llc Alkyl quarternary ammonium tryptamines and their therapeutic uses
CN115297851A (zh) * 2019-12-31 2022-11-04 Tf科技企业 口溶膜及其生产和使用方法
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
EP4167992A1 (en) * 2020-06-22 2023-04-26 University of Zürich Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy
CA3188263A1 (en) * 2020-08-05 2022-02-10 Matthias Emanuel LIECHTI Intravenous dmt administration method for dmt-assisted psychotherapy
CA3192617A1 (en) 2020-09-20 2022-03-24 Matthew BAGGOTT Advantageous tryptamine compositions for mental disorders or enhancement
KR20240013170A (ko) * 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태

Similar Documents

Publication Publication Date Title
JP2025142338A5 (cg-RX-API-DMAC7.html)
BRPI0711168A2 (pt) composição transmucosal
CZ20013344A3 (cs) Farmaceutický prostředek vhodný pro léčení erektilní dysfunkce
JP2023076465A5 (cg-RX-API-DMAC7.html)
JP2013501718A5 (cg-RX-API-DMAC7.html)
US20210308040A1 (en) Ketamine oral transmucosal delivery system
JP2010504312A (ja) 活性成分の経粘膜投与のためのガレノス的方式
JP4597273B2 (ja) 経口組成物
CN101505724A (zh) 阿利吉仑的盖伦制剂
ES2324769T3 (es) Comprimido que comprende cetrizina y pseudoefedrina.
JP2023506545A (ja) アゴメラチンを含有する経粘膜治療システム
WO2018236678A1 (en) Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
Sheoran Buccal drug delivery system: A review
CN101460144A (zh) AchE-NMDA组合物干胶片
CN113597303B (zh) 含有阿戈美拉汀的经粘膜治疗系统
JP2025539650A (ja) レミマゾラムを含有する口腔粘膜送達システム
KR100708560B1 (ko) 미르타자핀을 포함한 경구 붕해성 조성물
CN100418526C (zh) 依贝沙坦在制备用来预防或治疗肺动脉高压的药物中的应用
ES2459203T3 (es) Tratamiento de combinación con fármacos
ES2309357T3 (es) Nueva combinacion sinergica que comprende roflumilast y formoterol.
US11583518B2 (en) Non-hormonal compositions and methods for male contraception
JP2007512270A (ja) デオキシペガニンの経口製剤およびそれらの使用
CN107249595A (zh) 灌肠剂
WO2006013914A1 (ja) 口腔粘膜投与剤
JP2006070027A (ja) 口腔粘膜投与剤